ABSTRACT
OBJECTIVES: This prospective, randomized, open-label study aimed to compare the effects of antihypertensive treatment based on amlodipine or hydrochlorothiazide on the circulating microparticles and central blood pressure values of hypertensive patients. METHODS: The effects of treatments on circulating microparticles were assessed during monotherapy and after the consecutive addition of valsartan and rosuvastatin followed by the withdrawal of rosuvastatin. Each treatment period lasted for 30 days. Central blood pressure and pulse wave velocity were measured at the end of each period. Endothelial, monocyte, and platelet circulating microparticles were determined by flow cytometry. Central blood pressure values and pulse wave velocity were recorded at the end of each treatment period. RESULTS: No differences in brachial blood pressure were observed between the treatment groups throughout the study. Although similar central blood pressure values were observed during monotherapy, lower systolic and diastolic central blood pressure values and early and late blood pressure peaks were observed in the amlodipine arm after the addition of valsartan alone or combined with rosuvastatin. Hydrochlorothiazide-based therapy was associated with a lower number of endothelial microparticles throughout the study, whereas a higher number of platelet microparticles was observed after rosuvastatin withdrawal in the amlodipine arm. CONCLUSIONS: Despite similar brachial blood pressure values between groups throughout the study, exposure to amlodipine was associated with lower central blood pressure values after combination with valsartan, indicating a beneficial interaction. Differences between circulating microparticles were modest and were mainly influenced by rosuvastatin withdrawal in the amlodipine arm.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Amlodipine/administration & dosage , Cell-Derived Microparticles/drug effects , Rosuvastatin Calcium/administration & dosage , Hydrochlorothiazide/administration & dosage , Hypertension/drug therapy , Antihypertensive Agents/administration & dosage , Prospective Studies , Drug Therapy, Combination , Flow Cytometry , Valsartan/administration & dosageABSTRACT
As estatinas são drogas que inibem a 3-hidroxi-3-metilglutaril coenzima A (HMG CoA) redutase...
Subject(s)
Humans , Aortic Valve Stenosis/complications , Aortic Valve Stenosis/therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Risk FactorsABSTRACT
A aterosclerose é a principal causa de síndromes coronarianas agudas, como a angina instável e o infarto do miocárdio. A despeito de considerável avanço no tratamento agudo e também em relação a sua estratificação, as síndromes coronarianas agudas permanecem como a causa mais comum de morte no mundo industrializado. Recentemente, o uso de estatinas foi capaz de modificar a evolução de eventos coronarianos se iniciado precocemente após a síndrome coronariana aguda. A despeito da riqueza de evidências a partir dos clássicos estudos de prevenção secundária, como 4S, LIPID e CARE, demonstrando a eficiência das estatinas, essas drogas são ainda subutilizadas. Atualmente, considerável quantidade de evidência em relação a efeitos pleiotrópicos tem sido relatada, estendendo o uso dessas drogas além da redução lipídica. Assim, reduzindo o risco trombótico, melhorando a função endotelial e diminuindo a inflamação, as estatinas são capazes de modificar a história natural da doença arterial coronariana.